MP29-12 CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH RELUGOLIX: A SINGLE CENTER EXPERIENCE

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP29-12 CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH RELUGOLIX: A SINGLE CENTER EXPERIENCE Parth Vipul Shah, Eric Victor Li, Anna Monika Busza, Mohammad Rashid Siddiqui, Jonathan Alexander Aguiar, Sai KSR Kumar, Clayton Neill, Mary Kate Keeter, Hiten Dilip Patel, Edward Matthew Schaeffer, and Ashley Evan Ross Parth Vipul ShahParth Vipul Shah More articles by this author , Eric Victor LiEric Victor Li More articles by this author , Anna Monika BuszaAnna Monika Busza More articles by this author , Mohammad Rashid SiddiquiMohammad Rashid Siddiqui More articles by this author , Jonathan Alexander AguiarJonathan Alexander Aguiar More articles by this author , Sai KSR KumarSai KSR Kumar More articles by this author , Clayton NeillClayton Neill More articles by this author , Mary Kate KeeterMary Kate Keeter More articles by this author , Hiten Dilip PatelHiten Dilip Patel More articles by this author , Edward Matthew SchaefferEdward Matthew Schaeffer More articles by this author , and Ashley Evan RossAshley Evan Ross More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003257.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Relugolix is an oral GnRH antagonist that was FDA approved in December of 2020 which causes rapid testosterone suppression and rebound upon discontinuation, and potentially decreases androgen deprivation therapy related cardiovascular events. We sought to determine the characteristics and cardiovascular outcomes of patients with prostate cancer treated with relugolix at our institution. METHODS: The Northwestern Electronic Data Warehouse was queried for men with an established diagnosis of prostate cancer for whom relugolix was prescribed between December 2020-July 2022. Baseline clinicopathologic characteristics, cardiac health information, Charlson comorbidity index (CCI), and cardiac outcomes following initiation of relugolix were collected. RESULTS: 230 men (mean age 70.5 years) were prescribed relugolix at our institution. Relugolix was most commonly prescribed by radiation oncology (38.3%, n=88), followed by medical oncology (33.5%, n=77), and urology (27.4%, n=63). Patients had high CCI (mean 7.5) and 69.1% had a history of cardiovascular disease or at least one cardiovascular disease risk factor prior to initiation of therapy (n= 159). The most common risk factors included history of dyslipidemia (49.1%, n=113) and hypertension (46.5% n=107). Following initiation of relugolix, 11 major adverse cardiac events, defined as non-fatal MI, non-fatal stroke, and death from any cause, were observed. Acute MI was the most common (n=3), followed by cerebral infarction (n=2) and TIA (n=2). A total of 4/230 (1.7%) patients died during the study period (n=2 cardiac arrest, n=2 other causes). CONCLUSIONS: The majority of patients who were prescribed relugolix had at least 1 cardiac comorbidity, and the subsequent rate of major adverse cardiac events was similar to the HERO registrational trial (4.8% vs 3.6%). Our findings illustrate a real-world experience of patients initiating therapy with relugolix, comorbidities present at initiation, providers managing the drug, and cardiovascular and survival outcomes following its use. Source of Funding: N/A © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e386 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Parth Vipul Shah More articles by this author Eric Victor Li More articles by this author Anna Monika Busza More articles by this author Mohammad Rashid Siddiqui More articles by this author Jonathan Alexander Aguiar More articles by this author Sai KSR Kumar More articles by this author Clayton Neill More articles by this author Mary Kate Keeter More articles by this author Hiten Dilip Patel More articles by this author Edward Matthew Schaeffer More articles by this author Ashley Evan Ross More articles by this author Expand All Advertisement PDF downloadLoading ...